

References:

1. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behloul H, Guo H, Pilote L. **Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.** *Circulation*. 2014 Mar 18;129(11):1196-203. doi: 10.1161/CIRCULATIONAHA.113.004777. Epub 2014 Jan 22. PMID: 24452752.
2. Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T. **Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.** *JAMA*. 2014 Mar 5;311(9):919-28. doi: 10.1001/jama.2014.1334. PMID: 24595776.
3. ELIQUIS Drug monograph: Pfizer: accessible at https://pdf.hres.ca/dpd_pm/00050173.PDF
4. XARELTO Drug monograph: Bayer: accessible at https://pdf.hres.ca/dpd_pm/00059600.PDF
5. LIXIANA drug monograph: Servier Canada in: accessible at https://pdf.hres.ca/dpd_pm/00063796.PDF
6. Apo- Dabigatran drug monograph: Apotex: accessible at https://pdf.hres.ca/dpd_pm/00043971.PDF
7. Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, Cox JL, Dorian P, Gladstone DJ, Healey JS, Khairy P, Leblanc K, McMurtry MS, Mitchell LB, Nair GM, Nattel S, Parkash R, Pilote L, Sandhu RK, Sarrazin JF, Sharma M, Skanes AC, Talajic M, Tsang TSM, Verma A, Verma S, Whitlock R, Wyse DG, Macle L; Members of the Secondary Panel. **The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.** *Can J Cardiol*. 2020 Dec;36(12):1847-1948. doi: 10.1016/j.cjca.2020.09.001. Epub 2020 Oct 22. PMID: 33191198.
8. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR; Peer Review Committee Members. **2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.** *Circulation*. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30. Erratum in: *Circulation*. 2024 Jan 2;149(1):e167. doi: 10.1161/CIR.0000000000001207. Erratum in: *Circulation*. 2024 Feb 27;149(9):e936. doi: 10.1161/CIR.0000000000001218. Erratum in: *Circulation*. 2024 Jun 11;149(24):e1413. doi: 10.1161/CIR.0000000000001263. PMID: 38033089; PMCID: PMC11095842.
10. Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, Kaewput W, Pachariyanon P, Cheungpasitporn W. **Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis.** *Pacing Clin Electrophysiol*. 2018 Jun;41(6):627-634. doi: 10.1111/pace.13331. Epub 2018 Apr 23. Erratum in: *Pacing Clin Electrophysiol*. 2018 Jul;41(7):879. doi: 10.1111/pace.13431. PMID: 29577340.
11. Siontis KC, Zhang X, Eckard A, Bhavne N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK. **Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.** *Circulation*. 2018 Oct 9;138(15):1519-1529. doi: 10.1161/CIRCULATIONAHA.118.035418. Erratum in: *Circulation*. 2018 Oct 9;138(15):e425. doi: 10.1161/CIR.0000000000000620. PMID: 29954737; PMCID: PMC6202193.
12. Moore M, Vizcaino K, Ewing JA, St Ville M. **Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis.** *J Am Pharm Assoc (2003)*. 2024 Mar-Apr;64(2):457-462. doi: 10.1016/j.japh.2023.12.020. Epub 2023 Dec 25. PMID: 38151201.
13. ClinicalTrials.gov . **Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis (SAFE-D).** (2019). Available online at: <https://clinicaltrials.gov/ct2/show/NCT03987711> (accessed July 23, 2021).
14. **Stroke prophylaxis with Apixaban in CKD5 patients with atrial fibrillation (SACK).** SACK trial information (2022) Available online at: <https://njurmed.se/stroke-prophylaxis-with-apixaban-in-ckd5-patients-with-atrial-fibrillation-sack>